Home Editor’s Pick Pfizer begins study of oral drug for prevention of COVID-19
imageWorld36 minutes ago (Sep 27, 2021 07:58AM ET)

(C) Reuters. FILE PHOTO: Pfizer logo is reflected in a drop on a syringe needle in this illustration photo taken March 16, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) -Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.

The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG (OTC:RHHVF), have been racing to develop the first antiviral pill for COVID-19.

Pfizer (NYSE:PFE) said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.

The trial would test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

Merck and partner Ridgeback Biotherapeutics said earlier this month they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection.

Pfizer had also said earlier this month it started a mid-to-late-stage trial of PF-07321332 for the treatment of COVID-19 in non-hospitalized, symptomatic adult patients.

Pfizer begins study of oral drug for prevention of COVID-19

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

EDITOR'S PICK

Pfizer begins study of oral drug for prevention of COVID-19

SUBSCRIBE HERE

CATEGORIES

Latest News